- Home
- SOWG vs LTRN Comparison
SOWG vs LTRN Comparison
Compare SOWG & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOWG | LTRN |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9M | 46.8M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SOWG | LTRN |
|---|---|---|
| Price | $3.07 | $2.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.4K | ★ 82.8K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $1.11 |
| 52 Week High | $4.45 | $4.70 |
Technical Indicators
Market Signals| Indicator | SOWG | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 31.76 |
| Support Level | $2.45 | $1.98 |
| Resistance Level | $3.50 | $2.41 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 52.13 | 25.32 |
Price Performance
Historical ComparisonAbout SOWG Sow Good Inc.
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.